DLBCL

>

Latest News

Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL

March 21st 2024

During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.

Brentuximab Vedotin Improves Survival in Relapsed/Refractory DLBCL
Brentuximab Vedotin Improves Survival in Relapsed/Refractory DLBCL

March 12th 2024

Utilization Challenges Hold Back the Adoption of Bispecific Therapies
Utilization Challenges Hold Back the Adoption of Bispecific Therapies

February 23rd 2024

Rizzieri Looks at Long-Term Efficacy of Combination Therapy in DLBCL
Rizzieri Looks at Long-Term Efficacy of Combination Therapy in DLBCL

February 17th 2024

What is the Best Dose of Lenalidomide? Lunning Provides His Analysis in R/R DLBCL
What is the Best Dose of Lenalidomide? Lunning Provides His Analysis in R/R DLBCL

February 16th 2024

Video Series
Video Interviews
Podcasts

More News